EVOTEC LAUNCHES “beLAB2122”, TRANSLATING ACADEMIC INNOVATION FROM LEADING GERMAN LIFE SCIENCE REGION IN COLLABORATION WITH BRISTOL MYERS SQUIBB

Hamburg, Germany, 13 April 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has launched beLAB2122, a translational $ 20 million BRIDGE in collaboration with Bristol-Myers Squibb Company (NYSE: BMY). beLAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects.

Read more